CAR-T trial deaths do not deter lupus patients hoping for a cure
Résumé détaillé
CHICAGO, Nov 11 - Lupus patients struggling with the debilitating disease are lining up to try experimental CAR-T therapies even after the recent deaths of four patients in…
CHICAGO, Nov 11 - Lupus patients struggling with the debilitating disease are lining up to try experimental CAR-T therapies even after the recent deaths of four patients in clinical trials for a variety of autoimmune diseases, according to doctors who treat the life-threatening condition.
The trials remain halted and full details of the deaths — three linked to Novartis and one to Bristol Myers Squibb — have not been released.
Still, patients are willing to take the risk, compelled by accounts of people with advanced disease who were able to stop all medications and reclaim normal lives.
"I have patients that are literally waiting to get in," said Dr. Anca Askanase, chief of rheumatology at the Hospital for Special Surgery in New York, who has enrolled patients in the Bristol Myers CAR-T trials.
Systemic lupus erythematosus, or SLE, the most common and severe form of lupus, causes agonizing joint pain and raises the risk of stroke, heart attack and kidney disease. Current treatments, which range from steroids to immunosuppressants and targeted biologics, often fail to control the disease. Some 10% to 15% of people with lupus die prematurely.
Brittan Kopittke, 27, who works for the University of North Carolina helping to counsel patients considering CAR-T, was diagnosed with lupus at age 22. SLE, which affects about 300,000 people in the US, typically develops between the ages of 15 and 44.
What began as a rash on her chest rapidly progressed to crippling joint pain, mouth sores and crushing fatigue. Steroids to reduce inflammation and the antimalarial drug hydroxychloroquine to tamp down antibodies attacking her healthy cells and tissues failed.
"My mouth sores were rampant. I was struggling to eat. I was struggling to drink. I was just very, very miserable," she said.
Despite trying a cocktail of medicines, her disease advanced, attacking her kidneys, heart and lungs.
Début de l'article, extrait de The Straits Times. Pour lire la suite, ouvrez l'article chez le média.
MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.straitstimes.com)



